PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2680763

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PROTEIN ENGINEERING CORPORATION	01/21/1997

RECEIVING PARTY DATA

Name:	DYAX CORP.
Street Address:	ONE KENDALL SQUARE
Internal Address:	BUILDING 600, FIFTH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13571138

CORRESPONDENCE DATA

Fax Number: (617)342-4001
Email: jrobins@foley.com, IPDocketing@foley.com
Correspondence will be sent via US Mail when the email attempt is unsuccessful.
Correspondent Name: MICHEL MORENCY
Address Line 1: 111 HUNTINGTON AVENUE
Address Line 2: FOLEY & LARDNER LLP
Address Line 4: BOSTON, MASSACHUSETTS 02199

ATTORNEY DOCKET NUMBER:	105493-0453
NAME OF SUBMITTER:	MICHEL MORENCY
Signature:	/ Michel Morency/
Date:	01/14/2014

Total Attachments: 4
source=Protein Engineering to Dyax Executed Assignment#page1.tif
source=Protein Engineering to Dyax Executed Assignment#page2.tif
source=Protein Engineering to Dyax Executed Assignment#page3.tif
source=Protein Engineering to Dyax Executed Assignment#page4.tif

WORLDWIDE ASSIGNMENT AND DECLARATION OF ACCEPTANCE

Effective December 31, 1996, PROTEIN ENGINEERING CORPORATION, of One Kendall Square, Building 600, Fifth Floor, Cambridge, MA 02139, a wholly owned subsidiary of DYAX CORP., hereby assigns to DYAX, CORP., of One Kendall Square, Building 600, Fifth Floor, Cambridge, MA 02139, all right, title and interest in the applications and patents identified below, including all rights of priority asserted therein, and in any continuations, divisions, continuations-in-part or extensions thereof, and DYAX CORP. hereby declares its acceptance of said assignment.

USSN 07/293,980, U.S. Patent No. 5,096,815, filed January 6, 1989, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3-USA);

USSN 07/558,011, U.S. Patent No. 5,198,346, filed July 26, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3.1-USA);

USSN 07/664,989, U.S. Patent No. 5,223,409, filed March 1, 1991, DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS (LADNER7-USA);

USSN 08/009,319, U.S. Patent No. 5,403,484, filed January 26, 1993, VIRUSES EXPRESSING CHIMERIC BINDING PROTEINS (LADNER7D-USA);

USSN 08/057,667, U.S. Patent No. 5,571,698, filed June 18, 1993, DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS (LADNER7E-USA);

USSN 08/415,922, filed April 3, 1995, VIRUSES EXPRESSING CHIMERIC BINDING PROTEINS (LADNER7F-USA);

USSN 08/358,160, filed December 16, 1994, ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE (LEY1-USA);

USSN 08/208,264, filed March 10, 1994, KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS (MARKLAND1A-USA);

USSN 08/676,125, filed July 11, 1996, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES (MARKLAND1B-USA);

USSN 08/676,124, filed July 11, 1996, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND3B-USA);

Canadian Appl. No. 610,176, filed September 1, 1989, GENERATION AND SELECTION OF NOVEL BINDING PROTEINS (LADNER1-CANA);

Canadian Appl. No. 2,105,300, filed February 27, 1992, PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS... (LADNER7A-CANA);

Canadian Appl. No. 2,105,304, filed February 28, 1992, INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN (LADNER7C-CANA);

Canadian Appl. No. 2,180,950, filed January 11, 1995, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES (MARKLAND1B-CANA);

Canadian Appl. No. 2,180,954, filed January 11, 1995, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND3B-CANA);

European Appl. No. EP89/910702.3, filed September 1, 1989, GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS (LADNER1-EPC);

European Appl. No. EP96/112867.5, filed September 1, 1989, GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS (LADNER1A-EPC);

European Appl. No. EP90/902453.1, filed January 5, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3-EPC);

European Appl. No. EP92/908057.0, filed February 27, 1992, PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS... (LADNER7A-EPC);

European Appl. No. EP92/908799.7, filed February 28, 1992, IMPROVED EPITOPE DISPLAYING PHAGE... (LADNER7B-EPC);

European Appl. No. EP92/908481.2, filed February 28, 1992, INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN (LADNER7C-EPC);

European Appl. No. EP95/909223.0, filed January 11, 1995, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND

ANALOGUES (MARKLAND1B-EPC);

European Appl. No. EP95/908460.9, filed January 11, 1995, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND3B-EPC);

Ireland Appl. No. IR89/2834, filed September 4, 1989, GENERATION AND SELECTION OF NOVEL BINDING PROTEINS (LADNER1-IREL);

Ireland Appl. No. 59\90, filed January 8, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS AND... (LADNER3-IREL);

Israeli Appl. No. 091,501, filed September 1, 1989, GENERATION AND SELECTION OF NOVEL BINDING PROTEINS (LADNER1-ISRA);

Japanese Appl. No. 1-510087, filed September 1, 1989, GENERATION AND SELECTION OF NOVEL BINDING PROTEINS (LADNER1-JAPA);

Japanese Appl. No. JP90/502436, filed January 5, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS AND... (LADNER3-JAPA);

Japanese Appl. No. 4-507558, filed February 27, 1992, PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS (LADNER7A-JAPA);

Japanese Appl. No. 5-508216, filed February 28, 1992, IMPROVED EPITOPE DISPLAYING PHAGE (LADNER7B-JAPA);

Japanese Appl. No. 4-508204, filed February 28, 1992, INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G (LADNER7C-JAPA);

Japanese Appl. No. 7-518726, filed January 11, 1995, KALLIKREIN-INHIBITING "KUNITZ DOMAINS" PROTEINS AND ANALOGUES (MARKLAND1B-JAPA);

Japanese Patent Application No. 7-518667, filed January 11, 1995, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND3B-JAPA);

PCT/US95/16349, filed December 15, 1995, ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE (LEY1A-PCT).

FOR PROTEIN ENGINEERING CORPORATION

Name L. Edward Cannon, Ph.D.

Title President

Date January 21, 1997

FOR DYAX CORP.

Name Henry E. Blair

Title Chairman & CEO

Date January 21, 1997

f:\user19\wp\d-f\prodyax.asg